Acumen Pharmaceuticals, Inc.

ABOS·NasdaqGS·Healthcare
Compare
0.2163−0.0181 (−7.72%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD
Pre-market0.2218+0.0055 (+2.54%)

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close0.2344
Open0.2300
Day range0.21630.2491
52-week range0.19803.6000
Off day high−13.17%
Off 52-week high−93.99%
Volume8.61M
Avg. volume (3M)2.20M
Market cap15.64M
EPS (TTM)-1.55
Forward P/E-0.44
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.45
Shares outstanding72.33M
Short interest6.13% of float
Earnings dateOct 26, 2026
Analyst target1.0000
Profit margin0.00%

Against its peers

Compare in full ›
ABOS ACIU ALEC VYGR KRSA ACAD
Market cap 15.64M 227.69M 254.58M 115.23M 1.39B 3.70B
P/E (TTM) — — — — — 9.6
Forward P/E -0.4 3.8 -3.1 -1.5 -8.6 23.3
Price/book 0.5 4.3 -25.6 0.7 -3.9 3.0
Dividend yield — — — — — —
1-year change −88.47% −33.62% +75.38% −57.14% +160.90% −7.88%
Today −7.72% +9.57% +11.22% +2.19% −4.38% +4.38%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All ABOS news ›
Seeking Alpha··3 outletsPositive

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Tina Ventura - Chief Investor Relations OfficerWilliam Sibold - CEO, President & DirectorDavid Soergel - Executive VP & Chief Medical OfficerMardi…

More from 2 other outlets
EquityBulls·Positive

Aarti Drugs Limited announces Q2, H1 FY27 results

03 Nov 2026, 10:59 PM IST Equity Bulls Stock Report Aarti Drugs Limited INE767A01016 Consolidated Financial Highlights – Q2 FY27 Looking ahead, we are building Aarti Drugs into a more integrated, more diversified and more globally relevant…

markets.businessinsider.com··2 outletsNegative

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months compared to placebo at…

More from 1 other outlet

From the 4Search news index, newest first.

In the news

61mentions in 30 days
39with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 61 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance